Skip to Main Content

Amid increasing debate over the cost of prescription drugs, a federal watchdog agency found the National Institutes of Health does not consider whether a medicine it discovered and licensed to a pharmaceutical company may later be affordable, and also fails to provide enough information about its licensing activities to assess patient access.

The failure to consider the impact that licensing has on public health, especially at a time when a growing number of Americans say they cannot afford their medicines, prompted the Government Accountability Office to recommend that the NIH do a better job of disclosing licensing data and pay more attention to the potential for anti-competitive practices that affect drug pricing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Mr Silverman , Thank you for your article . I do have a few questions about NIH and it’s licensing practices. In your research did you discover any way that the taxpayer gets reimbursed as deposits to the US Treasury from the license holder for the drugs that have been developed by the people at NIH?
    Do the people who developed these Drugs while working for NIH get to file patents in their name for the drugs they developed while working for the taxpayers ? Thanks for your time ,
    Mark Fitzsimmons

Comments are closed.